AbbVie Inc (ABBV)vsPrecipio Inc (PRPO)
ABBV
AbbVie Inc
$205.03
-0.52%
HEALTHCARE · Cap: $365.43B
PRPO
Precipio Inc
$29.98
-7.38%
HEALTHCARE · Cap: $53.51M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 261113% more annual revenue ($62.82B vs $24.05M). ABBV leads profitability with a 5.8% profit margin vs -1.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PRPO
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$168.19
Current Price
$205.03
$36.84 premium
Margin of Safety
-29.6%
Fair Value
$16.59
Current Price
$29.98
$13.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Revenue surging 22.9% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2.7% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : PRPO
The strongest argument for PRPO centers on Revenue Growth. Revenue growth of 22.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.
Bear Case : PRPO
The primary concerns for PRPO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while PRPO is a growth play — different risk/reward profiles.
PRPO carries more volatility with a beta of 1.38 — expect wider price swings.
PRPO is growing revenue faster at 22.9% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Precipio Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?